Dr. Hope E. Uronis, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 192
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: New York Medical College
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Internal Medicine Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 192
- Services billed
- 887
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 198 | 93 |
| Established patient office or other outpatient visit, 30-39 minutes | 137 | 82 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 59 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 49 | 42 |
| New patient office or other outpatient visit, 60-74 minutes | 45 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 29 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $4,948 in total to this clinician.
| AstraZeneca UK Limited | $1,829 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $1,480 |
| Daiichi Sankyo Inc. | $1,440 |
| Caris Mpi, Inc. | $130 |
| AstraZeneca Pharmaceuticals LP | $68.49 |
| Consulting Fee | $4,749 |
|---|---|
| Food and Beverage | $130 |
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Jul 18, 2025 | Consulting Fee | $1,829 |
| E.r. Squibb & Sons, L.l.c. Jul 17, 2025 | Consulting Fee | $1,480 |
| Daiichi Sankyo Inc. Nov 5, 2025 | Consulting Fee Enhertu · ONCOLOGY | $960 |
| Daiichi Sankyo Inc. Oct 29, 2025 | Consulting Fee Enhertu · ONCOLOGY | $480 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $134,665 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced …
Merck Sharp & Dohme LLC - M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Un…
AbbVie Inc. - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
AbbVie Inc. · Active, not recruiting · NCT06628310
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.